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The early treatment of urinary tract infections (UTIs) is directly related to decrease in
morbidity, which makes the empirical treatment of great importance. Recently, beta
lactamases of several types have emerged as significant mechanisms of resistance in
Gram-negative bacilli, especially Escherichia coli. Our aim was to study the urinary E. coli
isolated from Lebanese patients and to characterize their mechanisms of resistance. The
study analyzed data between 2005 and 2012 of UTIs caused by E. coli. The mechanisms
of resistance were characterized by phenotypic and genotypic methods and the pulsed-
field gel electrophoresis (PFGE) was used to determine the different bacterial clusters. As
expected, the highest incidence was observed with E. coli (60.53–73.98%) followed by
K. pneumoniae (5.32–8.33%). ICU isolates were constantly associated with the lowest
rates of susceptibility to extended-spectrum cephalosporins, ciprofloxacin, as well as
most of the tested antibiotics. A 100% occurrence of CTX-M in extended-spectrum β-
lactamase (ESBL)-producing isolates was recorded, followed by TEM, SHV, and OXA.
In addition, 15.9% harbored 4 different ESBL enzymes and only 13 isolates (14.8%)
harbored only one enzyme (CTX-M). Over the years, the simultaneous susceptibility of
E. coli to ceftazidime and ciprofloxacin decreased from 62.5% in 2006 to 48.7% in 2012.
PFGE results demonstrated that 10 clusters were 32 generated, denoting diversity among
detected isolates. Understanding the epidemiology of resistance is 33 instrumental for the
implementation of recommendations for the management of antimicrobials, infection 34
control measures, as well as active surveillance and antimicrobial stewardship.
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Introduction
The antimicrobials use and misuse have led to bacterial resistance. Urinary tract infections (UTIs)
are among the most common infectious diseases encountered in the community and in the hospital;
they result in high rates of morbidity and high economic costs associated with treatment (1–
3). In recent decades, the extended-spectrum β-lactamases (ESBLs) of the TEM, SHV, CTX-M,
and OXA type, as well as the CTX-M have emerged as significant mechanisms of resistance in
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TABLE 1 | Frequency of Gram-negative Bacilli-documented UTI isolates at the CHN hospital classified by year.
Total Nb of isolates Bacteria most frequently isolated from urinary tract infections
Escherichia
coli
Klebsiella
pneumoniae
Enterobacter
cloacae
Proteus
mirabilis
Pseudomonas
aeruginosa
2005 615 412 66.99% 38 6.18% 8 1.30% 25 4.07% 19 3.09%
2006 564 409 72.52% 30 5.32% 7 1.24% 24 4.26% 22 3.90%
2007 525 358 68.19% 29 5.52% 4 0.76% 30 5.71% 20 3.81%
2008 684 506 73.98% 57 8.33% 12 1.75% 23 3.36% 24 3.51%
2009 718 516 71.87% 56 7.80% 16 2.23% 41 5.71% 15 2.09%
2010 843 600 71.17% 61 7.24% 10 1.19% 52 6.17% 21 2.49%
2011 1162 694 59.72% 87 7.49% 16 1.38% 58 4.99% 38 3.27%
2012 1173 710 60.53% 91 7.76% 13 1.11% 59 5.03% 27 2.30%
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FIGURE 1 | Distribution of urinary E. coli in percent by location and
year.
Gram-negative bacilli (4). ESBLs are enzymes able to efficiently
hydrolyze extended-spectrum cephalosporins and monobactams
and have been associatedwith therapeutic failures. These enzymes
have widely spread to geographic regions, and this is due, in part,
to the fact that many resistance genes are often carried on self-
transmissible or mobile plasmids that are capable of spreading
horizontally between and within species (4, 5). In addition, car-
bapenem resistance, a worrisome public health threat, is being
reported throughout the world.
Early treatment of UTI is directly related to decrease inmorbid-
ity, whichmakes the selection of empirical therapy of great impor-
tance (6). The correct choice of empirical antimicrobial requires a
good understanding of the typical bacteriology involved in UTIs
(4–6), local resistance patterns, as well as the specific patient’s
antimicrobial and microbiologic history, all of which affect the
relative likelihoods of various organisms. Appropriate selection of
antimicrobial therapy is an important strategy in the prevention of
the spread of resistance, since use of overly broad therapy can lead
to development of resistance. Escherichia coli, a major component
of the intestinal flora, has been described as the most frequent
uropathogen involved in community as well as hospital-acquired
UTI (6–9). According to a study previously performed in Beirut
(10), E. coli was the most frequent isolate (60.64% of the total
isolates) and an increase in the production of ESBL was observed
between the years 2000 and 2009 (2.3–16.8%). Unfortunately, very
limited data concerningUTIs is available fromother regions of the
country. The north of Lebanon represents an important site for the
investigation of bacterial infection and resistance in view of the
many socio-cultural, economic, and medical practice differences.
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FIGURE 2 | Percentages of susceptibility of urinary E. coli to
ceftazidime and ciprofloxacin over the years. NS/S: trends of the isolates
non-susceptible to ceftazidime/susceptible to ciprofloxacin. S/NS: trends of
the isolates susceptible to ceftazidime/non-susceptible to ciprofloxacin. S/S:
trends of the isolates susceptible to ceftazidime/susceptible to ciprofloxacin.
NS/NS: trends of the isolates non-susceptible to ceftazidime/non-susceptible
to ciprofloxacin.
The purpose of this study was to investigate the bacterial etiology
of UTIs in one of the busiest hospitals of the north of Lebanon
(Centre Hospitalier du Nord) and to examine the epidemiologic
and microbiologic properties, including phenotypic and geno-
typic characterization of the mechanisms of resistance of E. coli
isolated from UTIs of Lebanese patients over an 8-year period.
Materials and Methods
Study Design
This study includes a retrospective part analyzing the data gener-
ated between January 2005 and January 2011, and a prospective
part dealing with the occurrence of beta-lactamases genes in
clinical isolates of E. coli between January 2011 and January 2013
and the related epidemiology of infection. Isolates of E. coli that
showed intermediate or full resistance to carbapenemswere stored
at  80°C until they were processed for analysis. Over the 8-year-
study, the population included all in and outpatients with positive
urine cultures for a Gram-negative bacillus (6284) regardless of
the type of UTI (complicated UTI, non-complicated UTI, acute
pyelonephritis, etc.). Histological and microbiological criteria for
positivity are cited below. In both the retrospective and prospec-
tive parts of the study, all urinary isolates data were collected and
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TABLE 2 | The rates of susceptibility of urinary and all isolates of E. coli between 2005 and 2012 is shown.
Percentages of susceptibility of E. coli isolated between 2005 and 2012
2005 2006 2007 2008 2009 2010 2011 2012
Urine
(412)
All
(454)
Urine
(408)
All
(493)
Urine
(358)
All
(484)
Urine
(506)
All
(629)
Urine
(516)
All
(650)
Urine
(600)
All
(743)
Urine
(694)
All
(821)
Urine
(710)
All
(831)
Amikacin 92:9 92:0 91:5 93:0 79:2 81:0 81:1 81:0 87:1 88:0 89:9 90:0 93:0 94:0 91:2 93:0
Amoxi–Clav 59:0 61:5 63:2 63:0 55:7 59:9 58:8 57:6 61:4 62:5 63:4 62:1 65:5 66:3 63:5 64:7
Ampicillin 29:8 29:0 31:4 30:0 26:3 26:0 27:0 26:0 30:4 29:0 28:6 28:0 31:0 34:0 29:3 31:0
Aztreonam 84:5 83:0 84:7 85:0 80:8 79:0 74:4 74:0 76:1 76:0 75:8 75:0 73:6 76:0 68:2 71:0
Cefepime 86:2 85:0 86:3 86:0 80:1 79:0 77:1 77:0 77:1 77:0 76:6 76:0 76:4 79:0 71:4 74:0
Cefotaxime 86:3 85:0 84:4 84:0 81:1 79:0 73:8 73:0 75:7 75:0 74:2 74:0 72:7 75:0 67:6 71:0
Cefoxitin 90:4 89:0 92:2 94:0 89:4 88:0 85:5 87:0 89:4 90:0 91:7 91:0 92:3 92:0 80:2 82:0
Ceftazidime 86:0 85:0 84:2 84:0 80:1 79:0 74:6 74:0 76:3 76:0 76:0 76:0 74:3 77:0 69:8 73:0
Cefuroxime 63:8 63:0 72:3 74:0 69:9 69:0 63:1 63:0 69:7 69:0 69:7 69:0 60:7 64:0 58:9 62:0
Ciprofloxacin 59:9 60:0 67:4 69:0 62:2 63:0 59:1 60:0 63:8 62:0 62:1 62:0 63:5 68:0 59:9 66:0
Fosfomycin 100:0 100:0 100:0 100:0 100:0 100:0 100:0 100:0 100:0 100:0 100:0 100:0 99:4 99:5 99:6 99:6
Gentamicin 61:8 70:0 59:6 68:0 53:6 50:0 54:8 51:0 56:5 58:0 51:4 51:0 52:4 46:0 54:3 55:0
Imipenem 100:0 100:0 100:0 100:0 100:0 100:0 100:0 100:0 100:0 100:0 100:0 100:0 99:9 99:8 99:9 99:6
Nitrofurantoin 93:4 94:0 92:9 93:0 90:1 91:0 92:0 92:0 91:6 92:0 94:9 95:0 95:9 97:0 95:9 96:0
Piperacillin 32:1 32:0 36:4 34:0 29:9 30:0 34:1 33:0 36:6 35:0 32:6 34:0 33:4 39:0 32:6 34:0
Pip-Tazo 86:3 85:0 86:4 86:0 71:2 70:0 74:5 75:0 79:5 80:0 85:5 87:0 87:4 89:0 84:1 84:0
Tigecycline ND ND ND ND ND ND ND ND ND ND ND ND ND 100:0 100:0 100:0
Tobramycin 67:8 67:0 70:0 70:0 56:6 56:0 51:4 53:0 59:0 59:0 48:8 48:0 42:4 47:0 49:2 53:0
Co-trimoxasole 68:6 70:0 68:1 68:0 67:4 70:0 69:4 70:0 68:7 69:0 65:5 64:0 63:3 65:0 58:4 62:0
ESBL rate (%) 11:6 12:6 13:9 13:9 17:3 18:3 21:8 23:6 21:1 22:1 21:9 23:4 23:8 24:6 25:3 29:4
ESBL, extended-spectrum beta lactamase.
entered into a database usingWHONET software. These datawere
classified based on frequency, department of origin, antimicrobial
susceptibility profiles, as well as etiology. Among the UTIs caused
by Gram-negative bacilli, there were 4,097 (65.2%) samples from
female patients and 2,187 (34.8%) from males. Adult patients
were sampled by clean catch midstream urine, and children aged
<3 years were sampled using sterile urine bags. Only a single
positive culture per patient was included in the analysis within the
period of 3months.
Isolation and Identification of Organisms
Samples for urine culture were tested within half an hour of
sampling. All samples were inoculated on Uriselect agar andMac-
Conkey agar and incubated at 37°C for 24 h, and for 48 h in case
no growth was observed after 24 h. A specimen was considered
positive for UTI in the light of the number of yielded colonies
(105 cfu/mL) and the cytology of the urine throughmicroscopic
detection of bacteriuria and PMNs (8 leukocytes/mm3). How-
ever, lower colony counts associated with significant pyuria or
low PMN count associated with significant colony counts was
considered and analyzed in the light of the clinical picture and the
patient’s immunological status. Bacterial identification was based
on standard culture and biochemical characteristics of isolates.
Gram-negative bacteria were identified by standard biochemical
tests (11, 12).
Antimicrobial Susceptibility Testing
Antimicrobial susceptibility of Enterobacteriaceae was tested by
the disk diffusion method according to CLSI recommendations,
using Mueller–Hinton agar (13). Antimicrobial agents tested
were ampicillin, amoxicillin–clavulanic acid, aztreonam,
cefoxitin, cefuroxime, cefotaxime, ceftriaxone, ceftazidime,
cefepime, piperacillin, piperacillin–tazobactam, imipenem,
meropenem, gentamicin, tobramycin, norfloxacin, ciprofloxacin,
trimethoprim–sulfamethoxazole, and tigecycline (all disk charges
were chosen as per the CLSI recommendations)
Statistical Analysis
Variables were expressed as percentages.
Phenotypic Detection of Resistance
The phenotypic detection of ESBL was done by the dou-
ble disk synergy test (DDST). In brief, ceftazidime (30mg),
cefepime (30mg), aztreonem (30mg), and cefotaxime (30mg)
disks (Oxoid) were placed 25mm (center to center) from the
amoxicillin/clavulanic acid (20/10mg) disk on Mueller–Hinton
agar plate inoculated with the test organism; the presence of
a keyhole effect was recorded 24 h after incubation. Resistance
to carbapenems was detected as described by Birgy et al. (14).
In this method, ertapenem, imipenem, and meropenem were
tested on Mueller–Hinton agar plates (MHA) impregnated with
5mM of EDTA, 10mg/mL of phenyl boronic acid (PBA), and
250 μg/mL cloxacillin (embedded) were used, respectively, for
the detection of metallo-β-lactamases (MBLs), Klebsiella pneu-
moniae carbapenemases (KPCs), and overproduction of AmpC.
Additionally, disks of amoxicillin–clavulanic acid, ceftazidime,
cefotaxime, and cefepime were added and arranged in a manner
where a keyhole effect could be observed for the detection of
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FIGURE 3 | Continued
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FIGURE 3 | Percentages of susceptibility of urinary isolates of E. coli in all/in/and out-patients. (A) Amikacin. (B) Ampicillin. (C) Amoxicillin–clavulanic acid.
(D) Cefuroxime. (E) Cefoxitin. (F) Ceftazidime. (G) Aztreonam. (H) Imipenem. (I) Nitrofurantoin. (J) Trimethoprim–sulfamethoxazole. (K) Ciprofloxacin.
ESBL production, and this provided an additional step for ESBL
detection in view of the enhanced keyhole effect observed in pres-
ence of EDTA and/or PBA. Resistance to temocillin was used for
the phenotypic detection of Oxa-48 carbapenemase. E. coliATCC
25922 was used as ESBL-negative and K. pneumoniae 700603 was
used as ESBL-positive reference strains.
Genotypic Detection of Resistance Genes
Multiplex PCR (four plex) was used to determine the presence
blaTEM, blaSHV, blaCTX-M, and blaOXA (15). Primers used for
these genes were: blaSHV – 237bp (F50-CTTTATCGGCCCTCA
CTCAA-30, R50-AGGTGCTCATCATGGGAAAG-30), blaTEM –
445bp (F50-CGCCGCATACACTATTCTCAGAATGA-3 0, R50-
ACGCTCACCGGCTCCAGATTTAT-30), blaCTX-M – 593 bp
(50-ATGTGCAGYACCAGTAARGTKATGGC-30, R50-TGGGTR
AARTARGTSACCAGAAYCAGCGG-30), blaOXA – 813 bp (F50-
ACACAATACATATCAACTTCGC-30, R50-AGTGTGTTTAGA
ATGGTGATC-30). PCRwas performed as follows: 15min at 95°C,
30 s at 94°C (30 cycles), 90 s at 62°C (30 cycles), 60 s at 72°C
(30 cycles), 10min at 72°C. The amplicons were tested by gel
electrophoresis. The PCR mix of this reaction included 10 μl of
master mix, 4 μl of primers mix, 1 μl of DNA, 5 μl of water.
For the detection of carbapenemases, 2 μl of total DNA was
subjected to multiplex PCR in a 50-μL reaction mixture. The mix
for the detection of blaIMP, blaVIM, and blaSPM genes contained
1 PCR buffer [10mmol/L Tris–HCl (pH 8.3), 50mmol/L KCl],
1.5mmol/L of MgCl2, 0.125mmol/L of each deoxynucleotide
triphosphate, 10 μmol/L of each primer, and 2U of AmpliTaq
Gold Polymerase (Roche, Meylan, France). The mix for the
detection of blaKPC, blaNDM, blaBIC, and blaOXA-48 was the same
concentration. Themix for the detection of blaAIM, blaDIM, blaGIM,
and blaSIM contained 1 PCR buffer [10mmol/L Tris–HCl (pH
8.3), 50mmol/L KCl], 3mmol/L of MgCl2, 0.125mmol/L of each
deoxynucleotide triphosphate, 10 μmol/L of each primer, 3 μL
of dimethyl sulfoxide, and 2U of AmpliTaq Gold Polymerase.
Amplification was carried out with the following thermal
cycling conditions: 10min at 94°C and 36 cycles of amplification
consisting of 30 s at 94°C, 40 s at 52°C, and 50 s at 72°C, with
5min at 72°C for the final extension. DNA fragments were
analyzed by electrophoresis in a 2% agarose gel at 100V for 1 h
in 1 TAE [40mmol/L Tris–HCl (pH 8.3), 2mmol/L acetate,
1mmol/L EDTA] containing 0.05mg/L ethidium bromide. The
primers were as follows (5’–3’): blaIMP – 232 bp (F GGAATA
GAGTGGCTTAAYTCTC, R GGTTTAAYAAAACAACCACC),
blaSPM – 271 (F AAAATCTGGGTACGCAAACG, R ACATTAT
CCGCTGGAACAGG), blaAIM – 322 (F CTGAAGGTGTACG-
GAAACAC, R GTTCGGCCACCTCGAATTG), blaVIM – 390 (F
GATGGTGTTTGGTCGCATA, R CGAATGCGCAGCACCAG),
blaOXA-48 – 438 (F GCGTGGTTAAGGATGAACAC, R CATC
AAGTTCAACCCAACCG), blaGIM – 477 (F TCGACACAC-
CTTGGTCTGAA, R AACTTCCAACTTTGCCATGC), blaBIC –
537 (FTATGCAGCTCCTTTAAGGGC, R TCATTGGCGGTGC
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TABLE 3 | Profiles of susceptibility of urinary E. coli isolated between 2005 and 2008 grouped by location.
Percentages of susceptibility of urinary isolates of E. coli 2005–2008
Nb (%) AMK AMP AUG CFX FOX CTX CAZ FEP AZT IMP CIP NIT SXT
2005
Urinary samples from all patients (412) 92:9 29:8 43:2 63:8 90:4 86:3 86:0 86:2 84:5 100 59:9 93:4 70:5
Out-patient 193 (46:81) 95:1 36:2 48:8 72:8 94:4 91 91:8 92:3 90:7 100 66:3 94:5 72:1
Medical wards 83 (20) 90:8 24:2 41:8 52:7 83:9 80:3 76:9 79:3 75:9 100 50:6 90 70:1
Surgery 63 (15:16) 92:1 24:6 30:4 52:2 85:7 81:2 79:4 79:4 79:4 100 49:2 90:9 71:6
Pediatrics 26 (6:37) 83:3 20:7 37:9 75:9 100 84:2 85:7 83:3 83:3 100 87:5 100 71:1
ICU 18 (4:4) 95 15 20 35 80 68:8 75 75 75 100 35 88:9 68:6
ER 17 (4:18) 94:1 26:3 47:4 57:9 94:1 93:3 89:5 88:2 88:2 100 70:6 94:4 71:5
Maternity 12 (2:86) 100 38:5 69:2 84:6 91:7 100 100 100 100 100 66:7 100 71:5
2006
Urinary samples from all patients (408) 91:5 31:4 53:2 72:3 92:2 84:4 84:2 86:3 84:7 100 67:4 92:9 68:6
Out-patient 211 (51:78) 93:6 36:2 61:5 78:4 93:1 87:6 88:1 90:3 88 100 71:1 97:2 69:7
Medical wards 75 (18:29) 89:6 20:8 35:1 61 84:4 76:6 72:7 76:6 76:6 100 57:1 83:1 68:1
Surgery 48 (11:4) 93:8 41:7 64:6 81:2 93:8 93:8 97:9 95:8 95:8 100 62:5 87:5 7:2
ER 26 (6:18) 92:3 23:1 53:8 84:6 100 92:3 88:5 92:3 92:3 100 80:8 96:2 68:9
Pediatrics 23 (5:23) 95:5 18:2 27:3 50 100 68:2 63:6 68:2 63:6 100 86:4 90:9 67:4
ICU 18 (4:51) 63:2 21:1 36:8 36:8 84:2 68:4 73:7 73:7 73:7 100 31:6 89:5 69:7
Maternity 7 (1:66) 100 42:9 42:9 85:7 100 85:7 85:7 85:7 85:7 100 100 100 69:2
2007
Urinary samples from all patients (358) 79:2 26:3 40:7 69:9 89:4 81:1 80:1 80:1 80:8 100 62:2 90:1 68:2
Out-patient 174 (48:53) 81:7 30:4 44:2 75:1 92:3 85 84 84:5 84 100 69:1 100 72:3
Medical wards 72 (20:11) 82:7 29:3 40 61:3 89:3 80 80 74:7 80 100 61:3 80:8 69:7
Surgery 46 (12:87) 79:2 22:9 37:5 70:8 85:4 77:1 75 79:2 78:7 100 47:9 90:9 70:8
ER 25 (6:97) 84:6 23:1 38:5 76:9 80:8 88:5 84:6 88:5 88:5 100 61:5 100 69:4
ICU 22 (5:9) 45:5 4:5 18:2 31:8 72:7 45:5 45:5 45:5 45:5 100 27:3 85:3 67:8
Pediatrics 11 (2:95) 81:8 18:2 72:7 81:8 100 81:8 81:8 81:8 81:8 100 90:9 100 70:5
Maternity 8 (2:14) 75 12:5 12:5 87:5 100 100 100 100 100 100 75 94:4 68:9
2008
Urinary samples from all patients (506) 81:1 27:0 48:8 63:1 85:5 73:8 74:6 77:1 74:4 100 59:1 92:0 69:1
Out-patient 264 (50:96) 83:1 30:8 53:8 69:9 89:1 81:6 81:2 83:8 80:8 99:6 68:4 97:2 73:3
Medical wards 83 (16:09) 79:8 20:2 39:3 48:8 76:2 59:5 58:3 64:3 61:9 100 40:5 90 69:8
Surgery 71 (13:79) 81:9 23:6 45:8 55:6 77:8 66:7 68:1 70:8 68:1 100 43:1 100 70:6
ER 36 (6:9) 83:3 36:1 58:3 72:2 94:4 80:6 88:9 86:1 83:3 100 80:6 91:7 72:1
Pediatrics 25 (4:79) 72 24 44 64 100 68 76 76 72 96 68 42:9 71:3
ICU 20 (3:83) 65 15 30 45 75 45 45 45 45 100 35 50 68:4
Oncology 7 (1:34) 78:55 8:35 39:3 55:9 70:2 77:35 77:35 77:35 77:35 100 29:8 97:15 70:4
CGTACAC), blaSIM – 570 (F TACAAGGGATTCGGCATCG, R
TAATGGCCTGTTCCCATGTG), blaNDM – 621 (F GGTTTG-
GCGATCTGGTTTTC, R CGGAATGGCTCATCACGATC),
blaDIM – 699 (F GCTTGTCTTCGCTTGCTAACG, R CGTT
CGGCTGGATTGATTTG), blaKPC – 798 (F CGTCTAGTTCT-
GCTGTCTTG, R CTTGTCATCCTTGTTAGGCG).
Genotyping
Pulsed-field gel electrophoresis (PFGE) was carried out using
restriction enzyme XbaI (Invitrogen) and the PFGE CHEF MAP-
PER (Bio-Rad). The comparison for E. coli was made using the
Dice coefficient. The dendrograms were generated adopting the
UPGMA method (unweighted pair group method using arith-
metic averages) usingBionumerics software.DNAratiowas calcu-
lated on the Dice coefficient, and isolates were considered geneti-
cally related if the Dice coefficient correlation was 85% or higher.
Isolates with 85% and above relatedness were clustered using a red
frame.
Results
Over the 8-year period, a total of 6284 Gram-negative bac-
terial isolates was recovered from documented UTIs. Table 1
shows the Gram-negative bacilli most frequently isolated from
these positive urine cultures. As expected, the highest fre-
quency was observed with E. coli (60.53–73.98%) followed by
K. pneumoniae (5.32–8.33%), Proteus mirabilis (3.36–6.17%),
Pseudomonas aeruginosa (2.3–3.9%), and Enterobacter cloa-
cae (0.76–2.23%). Figure 1 shows the distribution of urinary
isolates of E. coli by location. Out-patient isolates predom-
inate over the years with a more or less stable percent of
occurrence.
Figure 2 is plotted based on scatterplot analysis of co-
susceptibility/non-susceptibility to ceftazidime and ciprofloxacin.
Over the years, the isolation of E. coli that are susceptible to both
antibiotics is decreasing (62.5% in 2006 and 48.7% in 2012), while
strains that are non-sensitive to both antibiotics are increasing
(13.5% in 2006 and 23.2% in 2012).
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TABLE 4 | Profiles of susceptibility of urinary E. coli isolated between 2009 and 2012 grouped by location.
Profiles of susceptibility of urinary isolates of E. coli 2009–2012
Nb (%) AMK AMP AUG CFX FOX CTX CAZ FEP AZT IMP CIP NIT SXT
2009
Urinary samples from all patients (516) 87:1 30:4 41:4 69:7 89:4 75:7 76:3 77:1 76:1 100 63:8 91:6 69:2
Out-patient 268 (51:87) 89:6 32 44:6 78 93:2 81:3 81:3 83:1 82 99:6 68:3 94:2 72:5
Medical wards 109 (13:06) 80 21:4 27:1 45:7 81:4 55:7 57:1 58:6 54:3 100 51:4 84:3 69:3
ER 85 (12:69) 92:6 42:6 51:5 83:8 94:1 89:7 91:2 89:7 91:2 100 75 91:2 71:9
Surgery 49 (11:19) 78:3 21:7 35 56:7 76:7 65 66:7 65 65 98:3 53:3 86:7 71:1
Pediatrics 25 (3:17) 94:1 23:5 23:5 64:7 94:1 64:7 64:7 64:7 64:7 100 70:6 100 67:4
ICU 18 (2:8) 66:7 6:7 13:3 13:3 60 40 40 40 40 100 6:7 93:3 70:1
Maternity 10 (1:87) 90 30 60 70 100 90 90 90 90 100 70 80 70:1
Oncology 7 (1:4) 94:45 44:45 61:15 72:25 100 80:55 80:55 80:55 80:55 100 63:9 91:65 71:1
2010
Urinary samples from all patients (600) 89:9 28:6 47:8 69:7 91:7 74:2 76:0 76:6 75:8 100 62:1 94:9 63:5
Out-patient 295 (49:19) 91:1 31:5 51:1 77:7 95:4 82 83:2 83:6 82:6 100 70:5 96:7 69:2
Medical wards 109 (18:23) 91:2 16:8 33:6 50:4 84:1 57:5 59:6 61:9 61:1 100 43:4 88:5 64:2
ER 99 (13:71) 88:2 34:1 56:5 76:5 97:6 80 78:8 80 80 100 70:6 95:3 68:9
Surgery 59 (8:23) 86:3 31:4 49 64:7 86:3 68:6 71:4 70:6 68:6 100 39:2 94:1 68:6
Pediatrics 26 (4:19) 92:3 26:9 61:5 69:2 84:6 69:2 73:1 73:1 73:1 100 69:2 96:2 68:1
ICU 20 (3:06) 73:7 0 0 26:3 68:4 31:6 52:6 42:1 47:4 100 31:6 100 63:4
Oncology 11 (1:61) 90 50 50 70 100 70 66:7 80 70 100 70 90 69:1
Maternity 8 (1:13) 100 57:1 71:4 85:7 85:7 100 100 100 100 100 100 100 68:7
2011
Urinary samples from all patients (694) 93:0 31:0 67:0 60:7 92:3 72:7 74:3 76:4 73:6 99:9 63:5 95:9 65:4
Out-patient 363 (52:27) 92:7 35:9 73:3 68:9 93:8 79:2 80:9 81:8 80:2 100 69:3 95:5 68:7
Medical wards 105 (15:21) 93:5 22 54:5 45:5 86:9 56:1 56:1 61:8 56:1 99:0 48:8 95:1 65:4
Surgery 99 (14:23) 93:9 29:8 67:5 50:9 92 62:3 66:7 70:2 64:9 100 57:9 95:6 68:6
ER 59 (8:47) 94:1 30:9 67:6 63:2 100 79:4 79:4 79:4 79:4 100 55:9 98:5 66:9
Pediatrics 26 (3:8) 90:3 19:4 58:1 54:8 83:9 71 74:2 77:4 71 100 74:2 100 64:1
ICU 20 (2:82) 90:9 13:6 31:8 36:4 77:3 59:1 59:1 63:6 59:1 100 54:5 95:5 64:3
Maternity 11 (1:47) 91:7 16:7 58:3 83:3 83:3 100 100 100 100 100 83:3 100 67:7
Oncology 8 (1:35) 100 14:3 41:65 35:3 100 63:7 63:7 63:7 63:7 100 54:15 93:75 67:4
2012
Urinary samples from all patients (710) 91:2 29:3 62:2 58:9 80:2 67:6 69:8 71:4 68:2 99:9 59:9 95:9 61:4
Out-patient 362 (51:01) 91:6 32:1 68:1 66:7 85:8 75:3 77 78:8 75:3 100 66:7 96:5 66:5
Medical wards 158 (22:25) 87:7 26:7 51:3 49:7 68:4 58:3 58:8 60:4 59:4 99:4 47:1 94:5 61:7
Surgery 89 (12:54) 93:4 25:5 60:4 51:9 75:5 61:3 64:8 66 62:3 100 49:1 94:3 62:5
ER 40 (5:56) 95:7 42:6 80:9 72:3 91:5 83 85:1 87:2 85:1 100 68:1 100 65:5
Pediatrics 23 (3:31) 96:4 25 60:7 57:1 82:1 60:7 64:3 64:3 60:7 100 75 89:3 60:6
ICU 19 (2:72) 95:7 8:7 30:4 21:7 73:9 26:1 30:4 39:1 21:7 95:7 56:5 100 60:3
TABLE 5 | Phenotypic and genotypic detection of the mechanisms of resistance in 88 urinary E. coli isolated in 2012.
Antimicrobial susceptibility patterns and genotypic profiles of ESBL-producing urinary isolates of Escherichia coli
Phenotype Genotype of
resistance
CTX-M+SHV+
TEM+OXA
CTX-M+SHV+
TEM
CTX-M+
TEM
CTX-M+
OXA
CTX-M+
SHV
CTX-M
Male Female ESBL CTX-M SHV OXA TEM
29 59 (AMC-G3C) 88 27 26 60 14 11 35 12 2 13
(32.96%) (67.04%) 88 (100%) (100%) (30.69%) (29.55) (68.19%) (15.9%) (12.5%) (39.7%) (16.6%) (2.3%) (14.8%)
Table 2 shows the susceptibility profiles of E. coli to the dif-
ferent antimicrobial agents. No major difference in susceptibility
is observed between the overall isolates and the urinary isolates.
The lowest percentage of susceptibility was manifested against
ampicillin reaching 26% in 2007. Over successive years, the sus-
ceptibility to third and fourth generations’ cephalosporins (repre-
sented by Ceftazidime in Figure 3F) and aztreonam (Figure 3G)
shows an obvious and constant decrease; this is coupled by an
increase in the production of ESBL as shown in Table 2 (12.6%
in 2005 and 29.4% in 2012 for all E. coli isolates). A similar pattern
of ESBL production is noted for the urinary isolates (11.6% in
2005 and 25.3% in 2012). Since 2008, a minimum of 10% sus-
ceptibility decrease to third and fourth generation cephalosporin
between in and out-patients isolates was observed. Such a dif-
ference is most likely due to the higher occurrence of ESBL and
AmpC in the hospital isolates. Figure 3K shows a considerably
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TABLE 6 | Phenotypic and genotypic characterization of the mechanisms of resistance in 5 E. coli isolated in 2012.
Antimicrobial susceptibility patterns and genotypic profiles of Carbapenems non-susceptible Escherichia coli isolates
Suggested phenotype of resistance Genotype of resistance
Specimen ESBL
(AMC-G3C)
MBL
(EDTA)
KPC-type AmpC OXA-48
(TMC)
ESBL IMP NDM-1 VIM OXA-48 SIM SPM KPC
(PBA and CLOXA)
Pus + +       CTX-M   +          
TEM
Urine         +         +      
Sputum +       + CTX-M       +      
SHV
Pus +       + CTX-M       +      
TEM
Urine +       + CTX-M       +      
TEM
ESBL, extended-spectrum beta-lactamase; MBL, metallo-beta lactamase; KPC, karbapenemase producing klebsiella; AMC, amoxicillin–clavulanic acid; G3C, third generation
cephalosporin, TMC, temocillin.
higher susceptibility of isolates from outpatients to ciprofloxacin,
although the general patterns of in- and out-patients’ isolates
are similar. The susceptibility to trimethoprim–sulfamethoxazole
is essentially the same for in and outpatients; however, it is
decreasing with time (Figure 3J). Susceptibility to nitrofurantoin
manifests an irregular pattern where the high rates in 2007 are sig-
nificantly decreased in in-patients, affecting therefore the overall
percentage of susceptibility; however, this antibiotic seems to keep
its high activity againstE. coli. Two imipenem-resistantE. coliwere
isolated fromUTIs in 2011 and 2012; of course, this does not affect
the pattern of susceptibility to this antibiotic (Figure 3H). Isolates
with decreased susceptibility to fosfomycin were observed in 2011
and 2012. Figures 3A and 3E show the patterns of susceptibility
to amikacin and cefoxitin respectively.
Tables 3 and 4 report the susceptibility profiles of the uri-
nary isolates of E. coli by location. ICU isolates were constantly
associated with the lowest rates of susceptibility to extended-
spectrum cephalosporins, ciprofloxacin, as well as most of the
tested antibiotics. Isolates coming from ER patients showed rates
of susceptibility similar to out-patients’ isolates.
A total of 88 isolates isolated in 2012 were subjected to molec-
ular testing for ESBL enzymes. Our results suggest a high corre-
lation between phenotypic and genotypic testing. A 100% occur-
rence of CTX-M in ESBL-producing isolates is recorded (Table 5),
followed by TEM, SHV, and OXA. In addition, 15.9% harbored
4 different ESBL enzymes and only 13 isolates (14.8%) harbored
only 1 enzyme (CTX-M).
On the other hand, concerning the five carbapenem-resistant
isolates of E. coli (two were urinary isolates), both phenotypic and
genotypic testing showed that OXA-48 was the most common
mechanism of carbapenem resistance (Table 6). Two of these
isolates came from pus, two from urine, and one from sputum
cultures. In both urinary isolates, OXA-48 was responsible for
resistance to imipenem.
On the other hand, the PFGE results of E. coli isolated in 2013
(Figure 4) demonstrated that 10 clusters were generated, denoting
diversity among detected isolates. However, those isolates falling
within the same cluster have a relatively high degree of relatedness
among them.
Discussion
Lebanon is currently witnessing an increase in the number of
bacterial infections that are associated with a wide spectrum of
resistance to common antimicrobial agents (16). The presence
of ESBL-producing organisms has been reported in hospitals as
well as in the community (17). In 1997, the percentage of ESBL-
producing E. coli and K. pneumoniae was 1.3 and 7.5%, respec-
tively, as compared to non-ESBL-producing strains of the same
species. This percentage, however, has increased over the years
[in 2001, the percentage of ESBL-producing E. coli reached 4%
(16, 18)]. Overall, there is a scarcity of data relating to antimi-
crobial resistance in the Middle East (16). Molecular analysis
revealed that CTX-M-15 is the most widespread ESBL since it
was present in 83% of the resistant strains. The reason behind
this increase of the frequency of occurrence of ESBL-producing
organisms is likely due to the misuse, and abuse of antibi-
otics (19).
Our results show that the northern part of Lebanon is not
different from the rest of the country. The rate of ESBLs increased
considerably over the course of the study period from 12.6 to 29.4
in all E. coli isolates and from 11.6 to 25.3% in urinary isolates.
This result correlates with the general trend in the country. In
addition to containing CTX-M-15, 30.7% of isolates tested pos-
itive for carriage of SHV, 29.6% for OXA, and 68.2% for TEM.
These results indicate that ESBL-producing organisms frequently
harbor more than one β-lactamase gene. In fact, 15.9% of E.
coli harbored all four ESBL enzymes and 14.8% harbored only
one gene of resistance (Table 5). Though this does not impact
the treatment strategy, harboring more than one gene of ESBL
enzymes makes the diversity of resistance gene carriage consid-
erably bigger.
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FIGURE 4 | Dendrogram generated by the PFGE of 88 urinary isolates of E. coli (2012).
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It is known that the occurrence of ESBL-producing E. coli
in high-risk areas of the hospital, such as ICUs, has increased
significantly (20, 21). In this context, bigger concern has
resulted from reports of the increasing frequency of ESBL-
producing organisms causing infections in outpatients. In our
study, most UTIs were isolated from out-patients. This sug-
gests an important spread of these enzymes in the community,
even if these outpatients’ infections are not entirely community
acquired and might correlate with hospital or health care facilities
visits.
Appropriate antibiotic treatment for infections caused by ESBL-
producing E. coli is significantly affected by the cross-resistance
to other antibiotics such as quinolones (22). Resistance to these
drugs has been shown to be related to the presence of a conjugative
plasmid associated with the ESBL phenotype. In this context,
carbapenems represent a good choice when therapy is needed for
serious infections.
In our study, co-resistance has been observed with fluoro-
quinolones and ceftazidime (Figure 2). While susceptible isolates
to both antibiotics remain the majority, the trend of occurrence
of these isolates is clearly decreasing over the years and is coupled
by an increase in resistance to either antibiotics. This implies that
fluoroquinolone resistance could be driven by cephalosporin use
at both hospital and community levels. Another implication of
this observation is that ciprofloxacin resistance may be associated
with limited treatment options for other classes of agents, as
observed in our study. The isolation of two carbapenem-resistant
E. coli fromUTIs should be carefully considered; their occurrence
foreshadows of a possible spread of carbapenemases into the
community.
Although the PFGE results show 10 clusters among the urinary
isolates of E. coli collected in 2013 with high level of similarity
(>95%), these results indicate genetic diversity yet all encoded the
CTX-M-15 type enzyme.
Limitations of the study include that some of the isolates
included in the analysis may have been associated with asymp-
tomatic bacteriuria rather than true UTI. While we used standard
surveillance criteria to define UTI, we allowed for some isolates
to be included without meeting those criteria if their clinical
picture was highly consistent with UTI. This had the potential to
introduce inter-observer variability in the determination of which
isolates were included. Furthermore, asymptomatic bacteriuria is
frequently associated with both high colony counts of bacteria and
significant pyuria, especially in the presence of a bladder catheter.
While the epidemiology of isolates obtained from patients with
asymptomatic bacteriuria should be similar to those from patients
with true infection, the public health implications are different,
since asymptomatic bacteriuria does not require treatment except
in rare circumstances.
In conclusion, ESBL-producing E. coli in urinary isolates is a
growing problem and is spreading over the whole country. This
study is among the first to provide information on the prevalence
and distribution of isolated E. coli with ESBL producer, possible
types of enzymes produced, clonal relationship, and susceptibility
to potentially active drugs in the north (2005–2012). This infor-
mation contributes to the understanding of the epidemiology of
resistance in the whole country as well as the implementation of
recommendations for the management of antimicrobials, infec-
tion control measures, and active surveillance and antimicrobial
stewardship is highly needed.
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